NASDAQ$DCTH

Delcath Systems Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Delcath reported first quarter 2024 results, highlighting revenue growth and strategic advancements.

Delcath Systems reported a significant increase in total revenue for Q1 2024, reaching $3.1 million compared to $0.6 million in the same period last year. The company is focused on expanding the availability of HEPZATO and is committed to reaching 20 treating centers by the end of 2024.

  • Recognized over $2.0 million in revenue from HEPZATO KIT sales and $1.1 million in CHEMOSAT sales.
  • Updated U.S. center activation guidance to a total of 20 active centers by the end of 2024.
  • Activated four treating centers during the first quarter, with an additional two in April.
  • Raised $7.0 million in a private placement transaction.

Headline financials

Total Revenue

$3.14M

Previous: $597K+425.8%
EPS

-$0.45

Previous: -$0.77+41.6%
Gross margin

71.0%

No prior period
R&D expenses

$3.7M

No prior period
SG&A expenses

$8.81M

No prior period
Adjusted EBITDA

-$7.33M

No prior period
Capital Expenditures

-$13K

Previous: $0.00
Free Cash Flow

-$11.1M

Previous: -$9M-23.6%
Net Income

-$11.1M

Previous: -$9M-23.5%
Operating Income

-$10.3M

Previous: -$8.33M-23.5%
Gross Profit

$2.24M

Previous: $416K+437.5%
Cash & Equivalents

$11.8M

Previous: $24.2M-51.4%
Total Assets

$36.1M

Previous: $30.6M+18.0%
R&D Expense

$3.7M

No prior period

Revenue & EPS history

Delcath · Revenue · Quarterly

$3.14M

Q1 2024+425.8%vs Q1 2023
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Forward guidance

Delcath is committed to expanding the availability of HEPZATO to patients in need and is confident that they will reach their goal of 20 treating centers by the end of 2024.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-2.1%

Avg return

Earnings day

+0.5%

Avg return

5 days after

+7.7%

Avg return

30 days after

28%

9 / 32 earnings

Positive

+37.5%

Q2 2019

Best reaction

-26.4%

Q3 2018

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.3%+0.6%-5.3%
Q4 2025-11.7%-15.8%-12.1%
Q3 2025-4.7%-9.2%+5.3%
Q1 2025+23.6%+31.7%+41.1%
Q4 2024-1.6%-12.1%-18.0%
Q3 2024-9.0%-14.0%+8.5%
Q2 2024-2.6%-4.2%+33.7%
Q1 2024+33.1%+40.2%+37.4%
Q4 2023+9.2%+2.4%+12.9%
Q3 2023-23.7%-16.9%+10.0%
Q2 2023-20.6%-23.3%+18.2%
Q1 2023+0.2%+7.8%+14.9%
Q4 2022+22.3%+18.8%+17.6%
Q3 2022-6.7%+0.0%+11.3%
Q2 2022-2.3%+10.2%-5.4%
Q1 2022-11.9%-16.7%-28.1%
Q4 2021+1.3%+2.8%+0.0%
Q3 2021-1.8%-5.0%-28.1%
Q2 2021-11.8%-13.5%+1.1%
Q1 2021-7.0%-0.6%+9.8%
Q4 2020-24.8%-7.2%-31.8%
Q3 2020+0.6%+3.6%+36.7%
Q2 2020-2.6%-4.6%-9.3%
Q1 2020-5.2%-5.2%+0.5%
Q4 2019+0.0%+13.8%+55.7%
Q3 2019-4.3%-4.3%-15.2%
Q2 2019+37.5%+27.5%+26.2%
Q1 2019-11.2%+0.0%+22.5%
Q4 2018-6.5%-8.9%-35.5%
Q3 2018-26.4%-0.3%-5.6%
Q2 2018+0.0%+19.0%+78.8%
Q1 2018+2.4%+0.3%-0.6%
Q4 2017
Q3 2017
Q2 2017
Q1 2017
Q4 2016
Q3 2016
Q2 2016
Q1 2016
Q4 2015
Q3 2015
Q2 2015
Q1 2015
Q4 2014
Q3 2014
Q2 2014
Q1 2014
Q4 2013
Q3 2013
Q2 2013
Q1 2013
Q4 2012
Q3 2012
Q2 2012
Q1 2012
Q4 2011
Q3 2011
Q2 2011
Q1 2011
Q4 2010
Q3 2010
Q2 2010
Q1 2010

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro